HomeClinical TopicsCardio-PulmonaryFDA approves Brilinta for ACSs

FDA approves Brilinta for ACSs

The U.S. Food and Drug Administration (FDA) has approved Brilinta (ticarelor) for reducing cardiovascular death and heart attack in patients with acute coronary syndromes (ACSs). Read more..


Please enter your comment!
Please enter your name here

Most Recent Content

For Nurse Practitioners

Couple talking to NP

Getting Covid Vaccine Won’t Hurt Pregnancy Chances; Getting Covid Could

Couples planning a pregnancy might be relieved to know that getting a Covid vaccine does not hurt their odds of conceiving, according to the...